Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?

Current Treatment Options in Oncology
Panayotis Kaloyannidis, John Apostolidis

Abstract

Nowadays, several novel agents have been introduced in the treatment of multiple myeloma, not only resulting in high response rates and prolonged survival but also offering good quality of life. However, the potential of cure, especially for patients with advanced or unfavorable disease features, remains elusive. Allogeneic hematopoietic stem cell transplantation, based mainly on the graft vs. myeloma effect, can offer prolonged disease control and probability of cure but unfortunately at the cost of considerable transplant-related toxicity rates. Therefore, the role of allogeneic hematopoietic stem cell transplantation in the treatment of multiple myeloma has been called into question. Recently, several studies, particularly those with long-term follow-up, demonstrated a trend of survival superiority for allografted patients with high-risk disease. These data fuel again the interest in allogeneic stem cell transplantation for selected patients with high-risk multiple myeloma, especially if the high remission rates which can be achieved with the currently used treatment protocols could be long-life sustained through the additional exploitation of the long-lasting anti-multiple myeloma effect, originating from the allograft.

References

Jan 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart BarlogieJohn C Crowley
Mar 16, 2007·The New England Journal of Medicine·Benedetto BrunoMario Boccadoro
Feb 26, 2008·Bone Marrow Transplantation·H de LavalladeM Mohty
Jul 10, 2008·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas y Grupo Español de Mieloma (PETHEMA/GEM)
Jun 21, 2011·Haematologica·Damien Roos-WeilUNKNOWN Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Jul 2, 2011·Critical Reviews in Oncology/hematology·Pellegrino MustoAntonio Palumbo
Jul 7, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bo BjörkstrandGösta Gahrton
Oct 4, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Francesca PatriarcaPaolo Corradini
Dec 1, 2011·Blood·Bruno PaivaUNKNOWN PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study G
Jan 11, 2012·American Journal of Hematology·Qaiser BashirMuzaffar H Qazilbash
Oct 20, 2012·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Nicolaus KrögerAxel R Zander
Apr 29, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Melissa AlsinaUNKNOWN Resource for Clinical Investigation in Blood and Marrow Transplantation
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboPhilippe Moreau
Sep 2, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eric SmithGuenther Koehne

❮ Previous
Next ❯

Related Concepts